18 subscribers
Gå offline med appen Player FM !
Innovating Approaches to Target Diseases of Aging with Jerry McLaughlin, CEO of Life Biosciences
Manage episode 430518550 series 2900042
In this episode, Ayesha spoke with Jerry McLaughlin, chief executive officer and board member of Life Biosciences, a company advancing innovative cellular rejuvenation platforms to reverse diseases of aging.
Life Biosciences is developing a gene therapy for primary open-angle glaucoma (POAG) and non-arteritic anterior ischemic optic neuropathy (NAION), two types of optic neuropathies with significant unmet needs. The company is developing innovative therapies for these indications that are based on innovative partial epigenetic reprogramming and chaperone-mediated autophagy technologies.
Jerry McLaughlin has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development and global commercialization of more than a dozen FDA-approved drugs with multiple successful exits. Jerry began his career at Merck and was extensively involved in multiple blockbuster product launches. Most recently, Jerry was President and CEO for Neos Therapeutics, Inc., a commercial stage pharmaceutical company. He holds a BA in economics from Dickinson College and an MBA from the Villanova School of Business.
Tune into the episode to learn more about the work Jerry is leading at Life Biosciences to better understand and target the biology of aging through innovative therapeutics for aging-related diseases with critical unmet medical needs.
For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media
Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
191 episoder
Manage episode 430518550 series 2900042
In this episode, Ayesha spoke with Jerry McLaughlin, chief executive officer and board member of Life Biosciences, a company advancing innovative cellular rejuvenation platforms to reverse diseases of aging.
Life Biosciences is developing a gene therapy for primary open-angle glaucoma (POAG) and non-arteritic anterior ischemic optic neuropathy (NAION), two types of optic neuropathies with significant unmet needs. The company is developing innovative therapies for these indications that are based on innovative partial epigenetic reprogramming and chaperone-mediated autophagy technologies.
Jerry McLaughlin has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development and global commercialization of more than a dozen FDA-approved drugs with multiple successful exits. Jerry began his career at Merck and was extensively involved in multiple blockbuster product launches. Most recently, Jerry was President and CEO for Neos Therapeutics, Inc., a commercial stage pharmaceutical company. He holds a BA in economics from Dickinson College and an MBA from the Villanova School of Business.
Tune into the episode to learn more about the work Jerry is leading at Life Biosciences to better understand and target the biology of aging through innovative therapeutics for aging-related diseases with critical unmet medical needs.
For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media
Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
191 episoder
Alle episoder
×1 Pioneering Cancer Treatment with Alpha Radiation Technology ft. Alpha Tau Medical CMO Dr. Robert Den 22:05
1 Innovations in Immunomodulators for Diseases of the Immune System ft. Dr. Judy Chou, CEO, AltruBio 35:23
1 Innovating Cell-Based Solutions for Type 1 Diabetes ft. Jonathan Rigby, CEO, Sernova 48:06
1 Immune-Based Intratumoral Cancer Therapies ft. Intensity Therapeutics founder and CEO Lewis Bender 41:51
1 Targeting Cancer Drug Resistance with Kairos Pharma’s CEO Dr. John Yu 27:59
1 Innovating Immunotherapeutics with Oncolytic Virus Therapy ft. Oncolytics Biotech’s CMO Dr. Thomas Heineman 46:19
1 Laser Vision: Pioneering Laser Innovations for Presbyopia ft. Ace Vision’s Dr. AnneMarie Hipsley 45:01
1 Bringing the Tech Revolution to Medicine with Digital Therapeutics ft. Click Therapeutics’ CMO Dr. Shaheen Lakhan 0:36
1 Inside the Latest Advances in Hearing Tech ft. Envoy Medical CEO Brent Lucas 36:40
1 Advances in Heart Failure Treatment ft. Dr. Robert Perkins, VP, US Medical Affairs/Renal, Bayer 20:23
1 Transforming Clinical Research: A Conversation with Morgan Hanger, Executive Director of CTTI 29:19
1 Innovative Approaches to Antiviral Drug Development 33:24
1 A Unique Approach to in vivo CAR T Therapy and New Advancements in the Field 32:19
1 The Promise of Epigenetic Therapeutics in Alcohol-Associated Hepatitis ft. DURECT President and CEO Dr. James Brown 32:33
1 Pioneering mRNA Therapies for Lung Diseases 34:15
Velkommen til Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.